Arcturus Therapeutics (ARCT)
Develops mRNA medicines for rare diseases and a CSL-partnered COVID-19 vaccine.
Something off on this page? Send us feedback.
Develops mRNA medicines through LUNAR delivery and STARR self-amplifying mRNA technology, targeting cystic fibrosis and ornithine transcarbamylase deficiency; KOSTAIVE is commercialized through CSL Seqirus. Revenue is centered on collaboration and grant arrangements rather than an internally marketed product line.
Develops mRNA medicines through its LUNAR lipid-delivery and STARR self-amplifying mRNA platforms. Its therapeutics pipeline includes LUNAR-CF (ARCT-032), a Phase 2 candidate for cystic fibrosis, and LUNAR-OTC (ARCT-810) for ornithine transcarbamylase deficiency.
The vaccine franchise centers on KOSTAIVE (ARCT-154), a self-amplifying mRNA COVID-19 vaccine developed with CSL Seqirus; it was marketed in Japan and received European Commission marketing authorization. CSL holds global collaboration rights, while ARCALIS is the company's Japanese mRNA-manufacturing joint venture.
The operating model combines internal rare-disease development with vaccine collaboration and grant revenue. Its progress therefore depends on clinical development and the CSL partnership.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 2, 2026 | Roth Capital | Reiterate | Rating: —Target: $20 | Target: $41 |
| Mar 18, 2026 | B. Riley Securities | Upgrade | ||
| Mar 4, 2026 | Piper Sandler | Reiterate | Rating: —Target: $140 | Target: $25 |
| Jan 22, 2026 | Roth Capital | Target | Target: — | Target: $20 |
| Oct 24, 2025 | HC Wainwright & Co. | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $191.5M · Total debt $22.9M · Total assets $224.3M · Shareholders' equity $171.8M
- Revenue
- $3.0M
- Operating income
- −$25.5M
- Net income
- −$23.8M
No dividends on record.
| Institutions | 88.72% | 25.22M shares | |
|---|---|---|---|
| 140 holders · as of Jun 30, 2026 | |||
| Insiders | 2.32% | 659.3K shares | |
| 3 holders · as of Dec 19, 2025 | |||
| Other | 8.96% | 2.55M shares | |
| remainder | |||
28.42M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Federated Hermes, Inc.Institution | 11.62% | 3.30M | as of Jun 30, 2026 |
Ark Investment Management LLCInstitution | 10.21% | 2.90M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 9.20% | 2.61M | as of Jun 30, 2026 |
Sumitomo Mitsui Trust Group, Inc.Institution | 6.91% | 1.96M | as of Jun 30, 2026 |
Nikko Asset Management Americas, Inc.Institution | 6.90% | 1.96M | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Vertex Pharmaceuticals
Dominant cystic-fibrosis therapy provider with genetic-medicine R&D
- Moderna
mRNA-vaccine company selling Spikevax and mNEXSPIKE
- Pfizer
COMIRNATY co-developer and commercial vaccine leader
- Ultragenyx Pharmaceutical
Rare-disease developer advancing an OTC gene-therapy program
- Sionna Therapeutics
CFTR-modulator developer with clinical NBD1 stabilizers
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Arcturus Therapeutics | $13.65 | −5.11% | $408.7M | — | — | 17.2 | −89.5% |
| Vertex Pharmaceuticals | $514.57 | −0.08% | $130.71B | 30.0 | 26.8 | 10.4 | +12.5% |
| Moderna | $184.00 | +0.79% | $72.44B | — | — | 32.5 | +2.1% |
| Pfizer | $27.96 | +0.09% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Ultragenyx Pharmaceutical | $14.76 | −5.48% | $1.54B | — | — | 2.1 | +28.5% |
| Sionna Therapeutics | $5.59 | −7.23% | $271.8M | — | — | — | — |
| Median | 33.4 | 18.4 | 6.4 | +7.5% |